Abstract
The historical background regarding the development of Rh-immune globulin for the prevention of Rh disease has been presented in brief. Following the extensive trials in Rh-negative male volunteers, a clinical trial on mothers was initiated, and the results after ten years' clinical experience with Rh-immune globulin have been presented. The incidence of sensitization among the Rh-negative mothers has been reduced from 14 to 1 per cent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
